Post job

Amylin Pharmaceuticals main competitors are Gilead Sciences, Ariad Pharmaceuticals, and Amgen.

Competitor Summary. See how Amylin Pharmaceuticals compares to its main competitors:

  • Johnson & Johnson has the most employees (134,500).
  • Employees at Gilead Sciences earn more than most of the competitors, with an average yearly salary of $99,828.
  • The oldest company is Johnson & Johnson, founded in 1886.
Work at Amylin Pharmaceuticals?
Share your experience

Amylin Pharmaceuticals vs competitors

CompanyFounding dateZippia scoreHeadquarters# of LocationsRevenueEmployees
1987
4.6
San Diego, CA1$650.7M1,300
1980
4.8
Thousand Oaks, CA9$33.4B22,000
1988
4.9
Tarrytown, NY7$14.2B9,123
1886
4.7
New Brunswick, NJ26$88.8B134,500
1997
4.7
Bothell, WA3$2.0B900
1891
4.6
Kenilworth, NJ31$64.2B74,000
1991
4.8
Cambridge, MA1$118.8M380
1992
4.9
Rockville, MD1$131.0M1,000
1952
4.9
Parsippany-Troy Hills, NJ6$9.3B11,300
1987
4.5
Foster City, CA9$28.8B11,800
1931
4.2
Deerfield, IL6$10.6B48,000
1978
4.7
Greensboro, NC5$1.8B9,400
1988
4.2
Gaithersburg, MD1$1.7B5,000
1989
4.1
Bothell, WA1$71.4M700
1986
4.5
South San Francisco, CA1$6.2M25

Rate how well Amylin Pharmaceuticals differentiates itself from its competitors.

Zippia waving zebra

Amylin Pharmaceuticals salaries vs competitors

Among Amylin Pharmaceuticals competitors, employees at Gilead Sciences earn the most with an average yearly salary of $99,828.

Compare Amylin Pharmaceuticals salaries vs competitors

CompanyAverage salaryHourly salarySalary score
Amylin Pharmaceuticals
$101,565$48.83-
Amgen
$93,349$44.88-
Regeneron
$85,589$41.15-
Johnson & Johnson
$76,686$36.87-
Seagen
$85,008$40.87-
Merck
$90,328$43.43-

Compare Amylin Pharmaceuticals job title salaries vs competitors

CompanyHighest salaryHourly salary
Amylin Pharmaceuticals
$148,032$71.17
Human Genome Sciences
$153,528$73.81
Regeneron
$149,503$71.88
Amgen
$148,853$71.56
Zoetis
$146,225$70.30
Ariad Pharmaceuticals
$144,885$69.66
Merck
$144,655$69.55
Med Immune Inc
$141,876$68.21
Seagen
$140,788$67.69
Gilead Sciences
$140,759$67.67
Icos
$139,693$67.16
Johnson & Johnson
$132,934$63.91
ConvaTec
$129,492$62.26
Baxter International
$129,349$62.19
Elan Pharmaceuticals
$122,746$59.01

Do you work at Amylin Pharmaceuticals?

Does Amylin Pharmaceuticals effectively differentiate itself from competitors?

Amylin Pharmaceuticals jobs

Amylin Pharmaceuticals demographics vs competitors

Compare gender at Amylin Pharmaceuticals vs competitors

Job titleMaleFemale
Merck54%46%
Gilead Sciences56%44%
Amgen57%43%
Johnson & Johnson58%42%
Baxter International59%41%
Amylin Pharmaceuticals--

Compare race at Amylin Pharmaceuticals vs competitors

CompanyWhiteHispanic or LatinoBlack or African AmericanAsianUnknownDiversity score
49%24%7%15%5%
9.7
57%19%9%11%4%
9.9
44%20%8%23%6%
9.8
54%16%10%15%4%
9.8
56%16%10%14%4%
9.8
54%15%10%17%4%
9.8

Amylin Pharmaceuticals and similar companies CEOs

CEOBio
Robert A. Bradway
Amgen

Robert A. Bradway is an American businessman. He is the chairman and chief executive officer of Amgen.

​Jose E. Almeida
Baxter International

José E. Almeida is a Brazilian businessman. He has served as the chairman and CEO of Baxter International, Inc. since January 2016. He worked for Tyco Healthcare from 1995 to 2002. He was president of Medical Devices division from October 2006 to June 2011. He served as chairman of the board of directors of Covidien since March 2012 and as the president, chief executive officer and a director since July 2011. He became a director of EMC Corporation on Jan 12, 2015 and resigned on October 30, 2015, due to his election as chairman and CEO of Baxter. In 2015, he worked for The Carlyle Group as an Operating Executive in the Global Healthcare group.

Daniel O’Day
Gilead Sciences

Joaquin Duato
Johnson & Johnson

Robert M. Davis
Merck

Robert M. Davis is corporate vice president and president of Baxter's Medical Products business. In this position, Davis oversees a range of products used in the delivery of fluids and drugs to patients, and in the treatment of end-stage kidney disease. Davis took on his current role in October 2010. Prior to this role, Davis served as corporate vice president and president of Baxter's Renal business. He served as corporate vice president and chief financial officer from 2006 through May 2010, and as treasurer from 2004 through 2006. Davis joined Baxter as treasurer in November 2004 from Eli Lilly and Company, where he served in numerous positions of increasing responsibility over 14 years. Davis currently serves on the Board of Trustees for Rush University Medical Center and also serves as a member of the Finance Committee. He also is a member of the Board of Directors of AdvaMed.

Roger D. Dansey
Seagen

Juan Ramón Alaix
Zoetis

Juan Ramón Alaix was appointed chief executive officer of Zoetis in July 2012. In this role, he leads the world’s largest company with a singular focus on animal health medicines and vaccines. He is a member of the Zoetis Board of Directors. Mr. Alaix served as President of Pfizer Animal Health since 2006, where he was responsible for the overall strategic direction and financial performance of the company. Under his leadership, the company generated annual revenue of $4.8 billion in 2015 with approximately 9,000 employees worldwide. Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in more than 100 countries. He joined Pfizer from Pharmacia in 2003 as Regional President. He has 35 years’ experience of increasing responsibility in finance, commercial and management, including 20 years in the pharmaceutical industry. In the 1990s, Mr. Alaix served in general management with Rhône-Poulenc Rorer in Spain and Belgium before becoming country President of Spain for Pharmacia in 1998. In 2013, Mr. Alaix completed a two-year term as President of the International Federation for Animal Health (IFAH), now known as HealthforAnimals, in addition to serving as a member of the board and executive committee. HealthforAnimals represents manufacturers of veterinary medicines, vaccines and other animal health products in both developed and emerging markets. Mr. Alaix continues to serve as a member of the HealthforAnimals board and executive committee. A native of Spain, Mr. Alaix received a graduate degree in economics from the Universidad de Madrid.

Johnson & Johnson
ConvaTec

Paul Clark
Icos

Amylin Pharmaceuticals competitors FAQs

Search for jobs